Post

New research · Internal Medicine
Cancer epidemiology · 3h
Cohort studyCancer epidemiology · 2026

Prediagnostic use of anticoagulant treatment in patients with renal cell carcinoma: Impact on stage distribution and postoperative prognosis.

Karen Marie Ingemann Brandt, Tommy Kjærgaard Nielsen, Loren Lipworth … Mette Nørgaard
Read paper
Internal MedicineCohort study

Anticoagulant use before diagnosis linked to higher 30-day readmission after kidney cancer surgery

Prediagnostic use of anticoagulant treatment in patients with renal cell carcinoma: Impact on stage distribution and postoperative prognosis.

Karen Marie Ingemann Brandt … Mette Nørgaard
Cancer epidemiology · 2026
Background

This study examined the association between prediagnostic anticoagulant use and stage at diagnosis, surgical outcomes, and mortality in patients with renal cell carcinoma (renal cell carcinoma).

Methods

In a nationwide register-based Danish cohort study, we included renal cell carcinoma patients undergoing partial or radical nephrectomy in Denmark in 2009-2020.

Results

anticoagulant users were readmitted within 30 days more often than non-users

AHR by subgroup · 95% CI
null = 1
but lower one-year mortality
0.81
one-year mortality
1.12
More results

Among 5730 renal cell carcinoma patients, 21.0% were current and 11.4% former anticoagulant users.

At diagnosis, the odds of having higher stage (stage III/ IV) was slightly lower among anticoagulant users (adjusted ORs were 0.90 [95% CI 0.71-1.00] for current users and 0.85 [95% CI 0.73-0.90] for former users).

More results

Current users had slightly higher 90-day mortality (adjusted hazard ratio [aHR] 1.10 [95% CI 0.65-1.88]), but lower one-year mortality (aHR 0.81 [95% CI 0.60-1.07]) compared with non-users.

Former users had slightly higher one-year mortality (aHR 1.12 [95% CI 0.82-1.54]).

“
Conclusion

Renal cell carcinoma patients with prediagnostic anticoagulant use had higher 30-day readmission rates but otherwise comparable perioperative outcomes and mortality to non-users, suggesting that prediagnostic anticoagulant use is not, in itself, a strong marker of poorer surgical prognosis.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Cohort Study
4.5 minutes
Each visual-field test averaged 4.5 minutes per eye.
Review
46.7%
nearly half of thyroid patients had Graves' disease, the most common overactive-thyroid condition
Cross-sectional
MYR 88,346.12
Average annual out-of-pocket expenditure for patients with cancer in Malaysia.
Case-control
5.4% Reduction in Odds of Neuropathy
each rise in zinc levels lowers the chance of nerve damage
Cross-sectional
SIR 9.93
risk climbs sharply when relatives cluster and clotting starts young
Cohort Study
67.8%
one-year survival was far worse than the intermediate-risk group's, roughly one in three died
Systematic Review
“Current evidence does not support universal thromboprophylaxis following ACLR.”